Department of Chest Diseases, Division of Immunology and Allergy, Faculty of Medicine, Erciyes University, Kayseri, Turkey
Department of Immunology and Allergy, Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
Turk J Med Sci. 2021 Aug 30;51(4):1953-1959. doi: 10.3906/sag-2009-41.
BACKGROUND/AIM: The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with mepolizumab in a real-life cohort are limited. Moreover, data about the effectiveness of mepolizumab on small airways is scarce. This study evaluated the effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, blood eosinophils, steroid dependence, and small airways in a real-life cohort of patients with SEA.
We retrospectively analyzed patients with SEA who were receiving fixed-dose mepolizumab. The effects of mepolizumab on clinical, laboratory, functional parameters were evaluated at 12th, 24th, and 52nd weeks. Small airways were assessed with the FEF 25-75.
A total of 41 patients were enrolled in the study. Mepolizumab significantly reduced asthma exacerbation rates, reduced mOCS dose, and improved asthma control test (ACT) scores at 12th, 24th, and 52nd weeks. However, we found no significant changes in FEV1 and FEF25-75 values at baseline, 12th, 24th, and 52nd weeks (78.9 ± 23.3%, 82.9 ± 23.4%, 81.9 ± 23.9%, and 78.9 ± 23.5% for FEV1; 45.1 ± 23.1%, 48.8 ± 23.5%, 48.7 ± 23.1%, and 41.0 ± 20.1% for FEF25-75, respectively)
In this study, mepolizumab significantly improved all outcomes (symptom scores, asthma exacerbations, OCS sparing, and blood eosinophils) except functional parameters. Still, despite the dose reduction in mOCS dosage, no significant deterioration was observed in FEV1 and FEF25-75 values.
背景/目的：美泊利珠单抗在严重嗜酸性粒细胞性哮喘（SEA）患者的临床试验中已得到广泛证实。然而，关于美泊利珠单抗在真实世界队列中的应用经验的报告有限。此外，关于美泊利珠单抗对小气道影响的数据也很少。本研究评估了美泊利珠单抗治疗在 SEA 真实世界队列中对症状、哮喘加重、血嗜酸性粒细胞计数、皮质类固醇依赖和小气道的有效性。
我们回顾性分析了接受固定剂量美泊利珠单抗治疗的 SEA 患者。在第 12、24 和 52 周时，评估美泊利珠单抗对临床、实验室和功能参数的影响。小气道采用 FEF 25-75 评估。
共纳入 41 例患者。美泊利珠单抗可显著降低哮喘加重率，减少 mOCS 剂量，并改善哮喘控制测试（ACT）评分，在第 12、24 和 52 周时。然而，我们发现基线、第 12、24 和 52 周时 FEV1 和 FEF25-75 值没有显著变化（FEV1 分别为 78.9 ± 23.3%、82.9 ± 23.4%、81.9 ± 23.9%和 78.9 ± 23.5%；FEF25-75 分别为 45.1 ± 23.1%、48.8 ± 23.5%、48.7 ± 23.1%和 41.0 ± 20.1%）。
在本研究中，美泊利珠单抗显著改善了所有结局（症状评分、哮喘加重、OCS 节省和血嗜酸性粒细胞计数），但功能参数除外。尽管 mOCS 剂量减少，但 FEV1 和 FEF25-75 值没有明显恶化。
